Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Multiple Sclerosis: Examining the Evidence
Share |

Multiple Sclerosis in 2011: Examining the EvidenceMultiple Sclerosis: Examining the Evidence

Highlights from a live CME seminar in Teaneck, New Jersey

Stuart D. Cook, MD; Patricia K. Coyle, MD; George C. Ebers, MD; Elliot Frohman, MD, PhD; John A. Lincoln, MD, PhD; Fred D. Lublin, MD; Wayne Moore, MD; Robert Naismith, MD; Jerry Wolinsky, MD

CME/CE Released: see session's release and expiration dates in the agenda section


For Physicians:
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation for Physicians
CMSC designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each segment is worth up to .5 credits.
Instructions for Receiving Credits

For successful completion of this activity and subsequent award of CME credit, participants are expected to view each session and submit the completed post-test and evaluation. You must receive a passing score as designated at the top of the test.

Target Audience
  1. Physicians
  2. Nursing professionals
  3. Healthcare professionals involved in the care of patients with multiple sclerosis (MS)
Disclosure of Relevant Financial Relationships
Giancarlo Comi, MD
Professorand Chairman, Department of Neurology
Director,Institute of Experimental Neurology
Vita-SaluteSan Raffaele University
SanRaffaele, Milan

Disclosurestatement: Consultant: Bayer Healthcare, Biogen Dompe, Merck Serono,Novartis, Sanofi Aventis, Serono Symposia International Foundation, Teva PharmaceuticalInd. Ltd.

Stuart D. Cook, MD
Ruth Dunietz Kushner and Michael Jay Serwitz Professor of Neurology/Neurosciences
University of Medicine and Dentistry of New Jersey (UMDNJ), New Jersey Medical School
Director, MS Diagnostic and Treatment Center, UMDNJ
Newark, NJ

Disclosure statement: Consultant: Bayer Healthcare, Biogen Idec, EMD Serono, Merck, Sanofi Aventis, Teva Neuroscience.

Patricia K. Coyle, MD
Professor, Acting Chair, Department of Neurology
State University of New York at Stony Brook
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosure statement: Consultant: Bayer Healthcare, Biogen Idec, EMD Serono, Novartis, Teva Neuroscience. Fees for Non-CME Services: Bayer HealthCare, Biogen Idec, EMD Serono, Novartis. Contracted Research: Novartis, Sanofi Aventis.

George C. Ebers, MD
Action Research Professor of Clinical Neurology
Wellcome Trust Centre for Human Genetics
Radcliffe Infirmary, University of Oxford,
Oxford, UK

Dr. Ebers has declared no significant financial relationships.

Elliot Frohman, MD, PhD
Professor with Tenure, Neurology and Ophthalmology
Kenney Marie Dixon-Pickens Distinguished Professor in Multiple Sclerosis Research
Irene Wadel and Robert Atha Distinguished Chair in Neurology
Director, Multiple Sclerosis Program
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Frohman has declared no significant financial relationships.

Douglas Goodin, MD
Professor,Department of Neurology
Universityof California, San Francisco
Director,UCSF Multiple Sclerosis Center

Disclosurestatement: Consultant: Bayer Healthcare, EMD Serono, Novartis, and TevaNeuroscience. Contracted Research: Novartis.

John A. Lincoln, MD, PhD
Assistant Professor, Department of Neurology
Multiple Sclerosis Research Group
University of Texas Health Science Center
Houston, TX

Disclosure statement: Consultant: Bayer Healthcare. Fees for Non-CME Services: Novartis.

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Mount Sinai School of Medicine
Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
New York, NY

Disclosure statement: Consultant: Abbott, Acorda, Actelion, Allozyne, Avanir, Bayer Healthcare, Biogen Idec, BioMS Medical, Celgene, EMD Serono, Genentech, Genmab, Medicinova, MorphoSys, Novartis, Pfizer, Questcor, Roche, Sanofi Aventis, Teva Neuroscience. Speaker's Bureau: EMD Serono, Pfizer, Teva Neuroscience. Sources of Funding for Research: Acorda Therapeutics, Biogen Idec, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Neuroscience. Stock Ownership: Cognition Pharmaceuticals.

Wayne Moore, MD
Clinical Professor of Neuropathology and Laboratory Medicine
University of British Columbia
Consultant Neuropathologist, Vancouver General Hospital
Vancouver, BC

Dr. Moore has declared no significant financial relationships.

Robert Naismith, MD
Assistant Professor of Neurology
John L. Trotter Multiple Sclerosis Center
Washington University
St. Louis, MO

Disclosure statement: Consultant: Acorda, Bayer Healthcare, Biogen Idec, Genzyme, Teva Neuroscience. Fees for Non-CME Services: Acorda, Bayer Healthcare, Biogen Idec, EMD Serono, Teva Neuroscience.

Jerry Wolinsky, MD
Bartels Family and Opal C. Rankin Professorship of Neurology
Director, Multiple Sclerosis Research Group
Director, Magnetic Resonance Imaging Analysis Center
University of Texas Health Science Center
Houston, TX

Disclosure statement: Consultant: BC Decker, Bayer Healthcare, Lilly, Novartis, Sanofi Aventis, Serono Symposia International Foundation, Teva, Teva Neuroscience. Contracted Research: Sanofi Aventis. Royalties: Millipore Corporation.

June Halper, MSN, ANP, FAAN
Founder and Executive Director
Consortium of Multiple Sclerosis Centers
Hackensack, NJ

Consultant: Acorda Therapeutics. Fees for Non-CME Services: Acorda Therapeutics.

Laurie Scudder DNP, NP has served as Nurse Planner and Reviewer for this activity. She has declared that she has no significant financial relationships.

The following planners and managers have no conflicts of interest to disclose: Joseph J. D'Onofrio, Katherine Wandersee.
Session 1
MS Diagnosis, Classification, and Pathology

Release Date: 12/23/2011; Expiration Date: 12/23/2012
Diagnosing MS (Patricia K. Coyle, MD)
MS Clinical Classifications (John Lincoln, MD, PhD)
Immunopathology/Neuropathology of MS (Wayne Moore, MD)

Learning Objectives
  1. List updated diagnostic criteria for MS and explain how they differ from previous criteria;
  2. Differentiate the stages of MS according to clinical criteria and describe determinants of disease progression;
  3. Summarize current knowledge about the neuropathological basis of MS.
Session 2
Clinical Monitoring of Disease Activity, Prognosis, and Therapeutic Decisions

Release Date: 3/30/2012; Expiration Date: 3/30/2013
The Role of Relapses: PRO (Fred D. Lublin, MD)
The Role of Relapses: CON (George C.Ebers, MD)

Learning Objectives
  1. Define the concept of relapse and the mechanisms of worsening MS;
  2. Distinguish progressive forms of disease from MS progression or worsening;
  3. Discuss and debate the impact of relapse on short-term and long-term MS outcomes.
Session 3
MRI is Important in Monitoring and Treatment Decisions

Release Date: 7/16/2012; Expiration Date: 7/16/2013
Role of MRI in Treatment Decisions: PRO (Stuart D. Cook, MD)
Role of MRI in Treatment Decisions: CON (Douglas S. Goodin, MD)

Learning Objectives
  1. Describe forms of MRI used in MS and how findings correlate with relapse, cognitive deficits, and disease progression;
  2. Evaluate the role of MRI in monitoring patient prognosis and making therapeutic decisions in MS;
  3. Compare and contrast the ability of MRI measurements versus clinical findings in evaluating long-term disability milestones in patients with MS.
Session 4
What is the Role of Optical Coherence Tomography?

Release Date: 11/15/2012; Expiration Date: 11/15/2013
Role of OCT: Neurologist's Perspective: PRO (Elliot Frohman, MD, PhD)
Role of OCT: Neurologist's Perspective: CON (Robert Naismith, MD)

Learning Objectives
  1. Describe the basis of OCT and describe its role as a biomarker of MS-related injury;
  2. Explain the relationship between retinal architecture and visual function;
  3. Analyze current research findings in OCT and its validity or lack of validity as a measure of disease activity in MS.
Session 5
Emerging Therapies: Will They Provide Us With Better Outcomes?

Release Date: TBA
Efficacy Data From Clinical Trials (Jerry S. Wolinsky, MD)
Safety Issues and Monitoring Requirements (Giancarlo Comi, MD)

Learning Objectives
  1. Identify newly introduced or emerging disease modifying therapies for multiple sclerosis;
  2. Review mechanisms and efficacy findings of emerging therapies for MS;
  3. Assess the major safety considerations of newer agents.
Technical Requirements

Processor Speed: 1.4 GHz P3
Memory: 256 MB RAM (20MB available)
Operating Systems Supported: Windows 2000/XP, MAC
Browsers Supported: Internet Explorer 5.5 or greater, Mozilla Firefox and Safari 3.525 or greater
Additional Requirements: Flash player 8.0 or greater, 800x600 Resolution or higher with 32-bit color
Connection Speed: 128 Kbps or better
Adobe Acrobat 6.0 or greater

Privacy Policy and Confidentiality

The CMSC respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in CME activities on our Website.

When you enroll in any of our course offerings, personal information is collected for the purpose of processing your registration and awarding CME credit. This information is not routinely shared with persons outside of the CMSC.

For questions regarding our Internet privacy policy, please contact the CMSC's Continuing Education Department.


Copyright @ 2011, CMSC. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the CMSC. The opinions expressed in this activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, or the CMSC.


Call Tina Trott at (201) 487-1050, ext. 102 or email

This online educational series is sponsored by the Consortium of Multiple Sclerosis Centers (CMSC). The live seminar was supported by a grant from Biogen Idec.

Links to the activity

Session 1 - MS Diagnosis, Classification, and PathologyAgree button

Session 2 - Clinical Monitoring of Disease Activity, Prognosis, and Therapeutic DecisionsAgree button

Session 3 - MRI is Important in Monitoring and Treatment DecisionsAgree button

Session 4 - What is the Role of Optical Coherence Tomography?Agree button
Sign In
Sign In securely
Latest News
Upcoming Events

5/24/2017 » 5/27/2017
2017 CMSC Annual Meeting

5/30/2018 » 6/2/2018
2018 CMSC Annual Meeting

5/29/2019 » 6/1/2019
2019 CMSC Annual Meeting

3 University Plaza Drive, Suite 116
Hackensack, NJ 07601
Tel: 201-487-1050 | Fax: 862-772-7275
Privacy Policy | Disclaimer